Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Will The Induced Pluripotent Stem Cell (iPSC) Market Valuation Change Between Now And 2029?

In recent times, the market size for induced pluripotent stem cell (ipsc) has witnessed a swift expansion. Projected to escalate from $3.3 billion in 2024 to $3.67 billion in 2025, it is expected to boast a compound annual growth rate (CAGR) of 11.3%. The historical growth can be associated with factors such as increasing healthcare expenditure, escalated funding, growing acknowledgment of the therapeutic potential of stem cell products, employment of induced pluripotent stem cell (IPSC) in drug discovery, rising demand for personalized medication, and the cost-effective advantages of IPSC in drug exploration.

Expectations are high for significant expansion in the induced pluripotent stem cell (ipsc) market over the upcoming years, with a projected growth reaching $5.29 billion by 2029. This growth translates to a compound annual growth rate (CAGR) of 9.6%. Factors contributing to this expected growth include an increasing number of chronic and genetic diseases, advancements in genomic projects and disease models derived from IPSC, as well as governmental initiatives and growth in technology. Key trends within the forecast period include the use of pluripotent stem cells in treating Parkinson’s disease (PD), increase in strategic collaborations and partnerships, the advancement of induced pluripotent stem cell IPSC-derived nk cells and cell therapy, investments in research and development of regenerative medicine, the introduction of IPSC expansion medium, personalized IPSC development, and potential treatment for type I diabetes using pluripotent stem cells.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2515&type=smp

What Growth-Enabling Forces Are Impacting The Induced Pluripotent Stem Cell (iPSC) Market?

The significant surge in chronic health conditions is a key factor fuelling the expansion of the induced pluripotent stem cell market. Chronic diseases such as cardio conditions, cancer, stroke, and diabetes can be effectively managed with the help of induced pluripotent stem cells. These are derived from the tissues of a child or an adult and are genetically altered to mimic the behavior of embryonic stem cells. The Partnership to Fight Chronic Disorder (PFCD)’s recent report indicates that approximately 45% of the 133 million Americans have at least one chronic health condition. Furthermore, approximately 1.7 million deaths in the USA, constituting seven out of every ten deaths, are related to these chronic conditions. These deaths can potentially be kept in check using induced pluripotent stem cell treatment. Such an increase in chronic ailments is spurring the need for the induced pluripotent stem cell treatment market.

What Are The Main Segment Classifications In The Induced Pluripotent Stem Cell (iPSC) Market?

The induced pluripotent stem cell (ipsc)market covered in this report is segmented –

1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cell Types

2) By Application: Academic Research, Drug Discovery And Toxicity Studies, Regenerative Medicine, Cell And Gene Therapy

3) By End-User: Hospitals, Research Laboratories

Subsegments:

1) By Hepatocytes: iPSC-Derived Liver Cells For Drug Toxicity Testing; Disease Modeling And Regenerative Therapies

2) By Fibroblasts: iPSC-Derived Skin Cells For Wound Healing And Tissue Repair; Fibroblast-Based Disease Research

3) By Keratinocytes: iPSC-Derived Skin Cells For Dermatological Research; Skin Regeneration Therapies

4) By Amniotic Cells: iPSC-Derived Cells For Prenatal Research; Amniotic Fluid-Based Regenerative Applications

5) By Other Derived Cell Types: Neurons For Neurological Disease Modeling; Cardiomyocytes For Heart Disease Studies; Endothelial Cells For Vascular Research

Which Emerging Trends Are Reshaping The Induced Pluripotent Stem Cell (iPSC) Market Landscape?

Firms operating within the Induced Pluripotent stem cell market are exploring strategic alliances and collaborations as a means to break into new areas and widen their product offerings. For instance, Bristol Myers Squibb and Century Therapeutics established a strategic alliance in January 2022 with the goal of creating IPSC-derived allogenic cell treatments for acute myeloid leukemia and multiple myeloma. Further, in May 2022, Evotec and Sernova declared a strategic partnership to work on the development of IPSC-based beta cell replacement therapies for the treatment of type 1 and type 2 diabetes.

Which Firms Are Driving Innovation Within The Induced Pluripotent Stem Cell (iPSC) Market?

Major companies operating in the induced pluripotent stem cell (iPSC) market include FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc, Takara Bio, Inc, Lonza Group AG, Astellas Pharma Inc, ViaCyte, Inc, Ncardia, REPROCELL USA, Inc, Japan Tissue Engineering Co., Ltd, Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, Takaria Bio, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, MSD, Pfizer, Roche, Pharmasyntez, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, GlaxoSmithKline, Parexel, Bayer, Fate Therapeutics, Athersys, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, VistaGen Therapeutics, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-global-market-report

What Are The Emerging Regional Trends Driving The Induced Pluripotent Stem Cell (iPSC) Market?

North America was the largest region in the induced pluripotent stem cell (IPSC) market in 2024. Western Europe was the second largest region in the global induced pluripotent stem cell (IPSC) market share. The regions covered in the induced pluripotent stem cell (IPSC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=2515&type=smp

Browse Through More Reports Similar to the Global Induced Pluripotent Stem Cell (iPSC) Market 2025, By The Business Research Company

Stem Cell Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/stem-cell-global-market-report

Stem Cell Cord Blood Banking Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report

Stem Cells Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/stem-cells-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model